Clinical trials: tuberculosis
Tuberculosis
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
This study will assess the safety of a Bacillus Calmette-Guérin (BCG) vaccine against tuberculosis (TB) and will evaluate if giving the vaccine by mouth, injection, or by both methods produces greater results.
- Trial name
- NCT00396370
- Testing
- BCG strain Connaught, BCG strain Danish
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential
This study is designed to assess the pharmacokinetics (PK), safety, and tolerability of Ganfeborole and Microgynon, an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG), when Microgynon is administered…
- Trial name
- NCT07784894
- Testing
- Ganfeborole, Microgynon
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis, Diagnoses Disease
Evaluating a New Stool Based qPCR for Diagnosis of Tuberculosis in Children and People Living With HIV
Stool4TB aims to evaluate an innovative stool-based qPCR diagnostic platform (with the capacity to become a POC diagnostic tool) in the high TB and HIV burden settings of Mozambique, Eswatini and Uganda, under the hypothesis that…
- Trial name
- Stool4TB (NCT05047315)
- Where
- 3 sites in Eswatini, Mozambique and 1 more
- Volunteers
- 1,967 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Latent Tuberculosis Infection
Clinical Trial of Mica
This study used a randomized, open, blank control design. A total of 6800 patients over 15 years old with latent mycobacterium tuberculosis infection who met the inclusion criteria but did not meet the exclusion criteria were…
- Trial name
- NCT05680415
- Testing
- Mycobacterium Vaccae for Injection
- Where
- 2 sites in China
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
This study will assess the safety and immunogenicity of 2 different formulations of tuberculosis vaccine GSK692342 in healthy adults.
- Trial name
- NCT00397943
- Testing
- GSK's candidate Mycobacterium tuberculosis vaccine 692342, Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system, Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis
The study is to enroll 60 participants aged 18-65 years old, including 30 healthy subjects and 30 tuberculosis patients. Low-dose (2.5 μg/ml), medium-dose (5 μg/ml), and high-dose (10 μg/ml) studies will be conducted separately…
- Trial name
- NCT06224608
- Testing
- Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chengdu CoenBiotech Co., Ltd
Tuberculosis
DAR-901 TB Booster Vaccine to Prevent TB in Adolescents
DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed with BCG to determine if immunization reduces the risk of TB infection
- Trial name
- DAR-PIA (NCT02712424)
- Testing
- DAR-901
- Where
- Tanzania
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Tuberculosis
Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US
This protocol will use leukapheresis to collect lymphocytes to study immune responses following vaccination with BCG in BCG-naïve participants.
- Trial name
- (A-051) (NCT03175380)
- Testing
- bacillus Calmette-Guérin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Aeras
Vitamin D Deficiency, Tuberculosis
Role of Vitamin D in Innate Immunity to Tuberculosis
The investigators proposed a pilot study preparatory to developing a randomized trial of vitamin D for the prevention of TB infection. The specific aims are presented below: 1.
- Trial name
- NCT01244204
- Testing
- Vitamin D
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Latent Tuberculosis
BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population
In the last decade, the incidence of tuberculosis (TB) has declined in much of the world, but has increased in Central and South America.
- Trial name
- PPT-BCG (NCT05541952)
- Testing
- BCG
- Where
- Brazil
- Volunteers
- healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Tuberculosis, Human Immunodeficiency Virus
Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons
Background: In Botswana, as in the rest of sub-Saharan Africa, undiagnosed TB or TB diagnosed late in the course of disease is thought to be the most common cause of death among HIV-infected persons.
- Trial name
- XPRES (NCT02538952)
- Testing
- Xpert device, Intensified TB Case Finding (ICF)
- Where
- Botswana
- Volunteers
- 18,696 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
According to WHO, about 40% of the incident TB cases in 2020 are either under-reported or under-diagnosed causing on one hand major health risks and on the other hand catastrophic financial consequences.
- Trial name
- NCT05526885
- Testing
- CAD4TB, POC-CRP, Xpert MTB/RIF Ultra
- Where
- 2 sites in Lesotho, South Africa
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Klaus Reither
Tuberculosis, Tuberculosis, Pulmonary
Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda
In a previous randomized control trial, the investigators identified gaps in the implementation of tuberculosis (TB) contact investigation at multiple levels of the service delivery cascade.
- Trial name
- HCD-CoP (NCT05640648)
- Testing
- User-Centered Implementation Strategy, Standard Implementation Strategy
- Where
- Uganda
- Volunteers
- 10,477 people, healthy volunteers welcome
- Sponsor
- Yale University
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis Infection, Latent, Tuberculosis Active
SCAF-TB - Saving Children and Their Families From Tuberculosis: Implementation Research to Improve TB Preventive Treatment Initiation and Completion Rates Among Contact Persons in Tajikistan and Tanzania
The SCAF-TB study aims to evaluate how the WHO-endorsed SIILTIBCY skin test can be best implemented to test close contacts for tuberculosis infection (TBI) in Tajikistan and Tanzania, either facility-based or home-based delivered…
- Conditions
- Tuberculosis Infection, Latent, Tuberculosis Active, TPT
- Trial name
- SCAF-TB (NCT07714707)
- Testing
- CY-TB Patch, Audiblehealth DX
- Where
- 2 sites in Tajikistan, Tanzania
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- KNCV Tuberculosis Foundation
Tuberculosis
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above.
- Trial name
- NCT07152639
- Testing
- 5μg/ml EEC, 5 unit（U） EC, 5 IU TB-PPD
- Where
- 8 sites in China
- Volunteers
- 1,784 people, healthy volunteers welcome
- Sponsor
- Chengdu CoenBiotech Co., Ltd
Tuberculosis
BCG Revaccination Study in Diabetic and Non-Diabetic Adults
The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2.
- Trial name
- NCT06246851
- Testing
- BCG Danish
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults
This Phase I study will be conducted as a randomized, double-blind, dose-escalation study in five groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis…
- Trial name
- NCT02074956
- Testing
- AERAS-404
- Where
- Finland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis, Pulmonary
Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia
Tuberculosis ( TB ) remains a major global public health problems and actions to ensure the diagnosis and complete treatment of all cases is the priority for the control of this disease.
- Trial name
- DOTS (NCT01945905)
- Testing
- Intramural, Extramural
- Where
- Colombia
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Fundación FES
Tuberculosis
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent.
- Trial name
- NCT03806699
- Testing
- ID93+GLA-SE
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.